Home/Filings/4/0000899243-22-035311
4//SEC Filing

Easom Eric 4

Accession 0000899243-22-035311

CIK 0001880438other

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 8:19 PM ET

Size

14.6 KB

Accession

0000899243-22-035311

Insider Transaction Report

Form 4
Period: 2022-11-03
Easom Eric
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    2022-11-03$15.67/sh11,082$173,68329,021 total
  • Sale

    Common Stock

    2022-11-04$15.80/sh8,828$139,47417,110 total
  • Sale

    Common Stock

    2022-11-07$15.90/sh10,167$161,7056,943 total
  • Sale

    Common Stock

    2022-11-03$16.02/sh3,083$49,37625,938 total
  • Sale

    Common Stock

    2022-11-07$16.72/sh2,036$34,0364,907 total
Footnotes (1)
  • [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0001914503

Filing Metadata

Form type
4
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 8:19 PM ET
Size
14.6 KB